,

K. Wenzel, C. N. Homann, G. Fabbrini, and C. Colosimo, The role of subcutaneous infusion 12 of apomorphine in Parkinson's disease, Expert Rev. Neurother, vol.14, pp.833-843, 2014.

R. Katzenschlager, W. Poewe, O. Rascol, C. Trenkwalder, G. Deuschl et al., , p.15

T. Henriksen, T. Van-laar, K. Spivey, S. Vel, H. Staines et al., Apomorphine 16 subcutaneous infusion in patients with Parkinson's disease with persistent motor 17 fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled 18 trial, Lancet Neurol, issue.18, pp.30239-30243, 2018.

M. Rosa-grilo, M. A. Qamar, A. Evans, and K. R. Chaudhuri, The efficacy of apomorphine20 A non-motor perspective, Parkinsonism Relat. Disord, vol.33, pp.28-49, 2016.

C. Trenkwalder, K. R. Chaudhuri, P. J. García-ruiz, P. Lewitt, R. Katzenschlager et al.,

T. Sixel-döring, Á. Henriksen, W. Sesar, M. Poewe, A. Baker et al., , p.24

S. Deuschl, G. Drapier, A. Ebersbach, H. Evans, S. Fernandez et al.,

S. Lees, J. C. Lewis, P. Martínez-castrillo, P. Martinez-martin, J. Odin et al.,

K. Tagaris and . Wenzel, Expert Consensus Group report on the use of apomorphine in the 27 treatment of Parkinson's disease-Clinical practice recommendations, Parkinsonism 28 Relat. Disord, vol.21, pp.1023-1030, 2015.

A. J. Yarnall, T. Lashley, H. Ling, A. J. Lees, S. Y. Coleman et al., , p.30

T. Revesz and D. J. Burn, Apomorphine: A potential modifier of amyloid deposition in 31

, Parkinson's disease?, Mov. Disord, vol.31, pp.668-675, 2016.

M. Alegret, F. Valldeoriola, M. Martí, M. Pilleri, C. Junqué et al., , p.33

, Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous 34 continuous infusion of apomorphine in Parkinson's disease, Mov. Disord, vol.19, pp.35-1463, 2004.

A. Antonini, I. U. Isaias, G. Rodolfi, A. Landi, F. Natuzzi et al., A 5-year 37 prospective assessment of advanced Parkinson disease patients treated with 38 subcutaneous apomorphine infusion or deep brain stimulation, J. Neurol, vol.258, pp.39-579, 2010.

M. Auffret, F. Le-jeune, A. Maurus, S. Drapier, J. Houvenaghel et al.,

M. Sauleau and . Vérin, Apomorphine pump in advanced Parkinson's disease: Effects on 42 motor and nonmotor symptoms with brain metabolism correlations, J. Neurol. Sci, vol.372, pp.279-287, 2017.

D. D. Gaspari, C. Siri, A. Landi, R. Cilia, A. Bonetti et al.,

E. Mariani, G. Sganzerla, A. Pezzoli, and . Antonini, Clinical and neuropsychological follow 2 up at 12 months in patients with complicated Parkinson's disease treated with 3 subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic 4 nucleus, J. Neurol. Neurosurg. Psychiatry, vol.77, 2006.

S. Drapier, A. Gillioz, E. Leray, J. Péron, T. Rouaud et al., , p.7

, Apomorphine infusion in advanced Parkinson's patients with subthalamic stimulation 8 contraindications, Parkinsonism Relat. Disord, vol.18, pp.40-44, 2012.

L. Morgante, G. Basile, A. Epifanio, E. Spina, A. Antonini et al.,

R. Martino, P. L. Marconi, V. Spina, A. E. Nicita-mauro, and . Di-rosa, Continuous 12 apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced 13

, Parkinson's disease: a follow-up of two years, Arch. Gerontol. Geriatr. Suppl, pp.14-291, 2004.

T. Van-laar, A. G. Postma, and M. Drent, Continuous subcutaneous infusion of apomorphine 16 can be used safely in patients with Parkinson's disease and pre-existing visual 17 hallucinations, Parkinsonism Relat. Disord, vol.16, pp.71-72, 2010.

R. W. Borgemeester and T. Van-laar, Continuous subcutaneous apomorphine, p.20

, Parkinson's disease patients with cognitive dysfunction: A retrospective long-term 21 follow-up study, Parkinsonism Relat. Disord, 2017.

K. Dujardin, A. J. Moonen, H. Behal, L. Defebvre, A. Duhamel et al., , p.24

C. Plomhause, A. F. Tard, and . Leentjens, Cognitive disorders in Parkinson's disease: 25 Confirmation of a spectrum of severity, Parkinsonism Relat. Disord, p.28, 2015.

C. Moreau, L. Defebvre, V. Fraix, C. Tranchant, K. Andre et al., , p.29

. Devos, Quality of life in Parkinson's disease improved by apomorphine pump: the 30 OPTIPUMP cohort study, J. Neurol, pp.1-9, 2016.

P. Martinez-martin, P. Reddy, R. Katzenschlager, A. Antonini, A. Todorova et al., , p.32

A. Henriksen, D. Martin, A. Calandrella, N. Rizos, A. Bryndum et al., , p.33

G. Timmermann, M. G. Ebersbach, M. Kramberger, K. Samuel, and V. Wenzel,

A. Tomantschger, H. Storch, Z. Reichmann, M. Pirtosek, P. Trost et al., , p.35

J. Palhagen, K. R. Volkmann, and . Chaudhuri, EuroInf: AMulticenter Comparative 36 Observational Study of Apomorphine and Levodopa Infusion in Parkinson's Disease, p.37

, Mov. Disord, vol.30, pp.510-516, 2015.

P. Martinez-martin, P. Reddy, A. Antonini, T. Henriksen, R. Katzenschlager et al., , p.39

A. Todorova, Y. Naidu, S. Tluk, C. Chandiramani, A. Martin et al., Chronic 40 subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease 41 compared to conventional therapy: a real life study of non motor effect, J. Park. Dis, vol.1, pp.197-203, 2011.

I. Litvan, J. G. Goldman, A. I. Tröster, B. A. Schmand, D. Weintraub et al.,

C. H. Mollenhauer, K. Adler, C. H. Marder, D. Williams-gray, J. Aarsland et al., , p.45

M. C. Rodriguez-oroz, D. J. Burn, R. A. Barker, and M. Emre, Diagnostic criteria for mild 46 cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force 47 guidelines, Mov. Disord, vol.27, pp.349-356, 2012.

E. Pirogovsky, D. M. Schiehser, I. Litvan, K. M. Obtera, M. M. Burke et al.,

L. Song, J. V. Liu, and . Filoteo, The utility of the Mattis Dementia Rating Scale in 50

, Parkinson's disease mild cognitive impairment, Parkinsonism Relat. Disord, vol.20, pp.1-627, 2014.

P. J. García-ruiz, Á. Sesar-ignacio, B. Ares-pensado, A. Castro, F. A. García et al., , p.3

M. Á. López, J. Arbelo-gonzález, J. Octavio, J. A. Burguera-hernández, and M. ,

C. Garriga, D. C. Blanco, B. García, and M. C. Cordero, J. Chacón, vol.5

A. E. Peña, A. Ibáñez, S. Onisalde, P. Giménez-roldán, and J. Granés-ibáñez,

H. Vara, R. Alonso, F. J. Jiménez, and J. Krupinski, J. Kulisevsky, vol.7

I. Bojarsky, E. L. Legarda-ramírez, J. C. García, and D. Martínez-castrillo,

F. González, P. Rodríguez, E. Mir, J. Muñoz-fargas, . Obeso et al., J. Olivares, vol.9

J. Romero, P. Olivé-plana, . Otermin, B. Vallejo, and . Sedano, , p.10

I. Rama, A. Pérez-lópez-fraile, V. Planas-comes, M. C. Puente-periz, and . Oroz, , p.11

D. Sevillano-garcía, P. Solís-pérez, J. Suárez-muñoz, J. Vaamonde, and C. Gamo, , p.12

F. Merino, . Valldeoriola, J. M. Serra, R. Y. Velázquez-pérez, and I. Baña, Zamarbide, vol.13

. Capdepon, Efficacy of long-term continuous subcutaneous apomorphine infusion in 14 advanced Parkinson's disease with motor fluctuations: A multicenter study

. Disord, , vol.23, pp.1130-1136, 2008.

J. Duprez, J. Houvenaghel, S. Drapier, M. Auffret, D. Drapier et al., , p.17

P. Sauleau, Continuous subcutaneous apomorphine infusion does not impair the 18 dynamics of cognitive action control in mild to moderate Parkinson's disease, J. Neurol, vol.19, pp.1-7, 2017.

H. Ma, M. Saint-hilaire, C. A. Thomas, and L. Tickle-degnen, Stigma as a key 21 determinant of health-related quality of life in Parkinson's disease, Qual, Life Res, vol.25, pp.3037-3045, 2016.